Alsup Laurie Smaldone

CIK: 0001589602

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)2 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

TBPH

Theravance Biopharma, Inc.

Director

ARVN

ARVINAS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

TBPH
Theravance Biopharma, Inc.
Sep 23, 2026
Disposition(D)
Direct
75K shares-
TBPH
Theravance Biopharma, Inc.
Sep 23, 2026
Disposition(D)
Direct
6K shares-
ARVN
ARVINAS, INC.
Jun 24, 2026
Award(A)
Direct
15.5K shares-
TBPH
Theravance Biopharma, Inc.
Jun 12, 2026
Award(A)
Direct
6K shares-
ARVN
ARVINAS, INC.
Jun 25, 2025
Award(A)
Direct
16K shares-
TBPH
Theravance Biopharma, Inc.
May 19, 2025
Award(A)
Direct
10.6K shares-

		Type	Shares	Price		Ownership
Sep 23, 2026	TBPH Theravance Biopharma, Inc.	Disposition(D)	74,980	-	$0	Direct
Sep 23, 2026	TBPH Theravance Biopharma, Inc.	Disposition(D)	6,009	-	$0	Direct
Jun 24, 2026	ARVN ARVINAS, INC.	Award(A)	15,527	-	$0	Direct
Jun 12, 2026	TBPH Theravance Biopharma, Inc.	Award(A)	6,009	-	$0	Direct
Jun 25, 2025	ARVN ARVINAS, INC.	Award(A)	16,025	-	-	Direct
May 19, 2025	TBPH Theravance Biopharma, Inc.	Award(A)	10,649	-	-	Direct

1-6 of 6 transactions

About Smaldone Alsup Laurie

Smaldone Alsup Laurie (SEC CIK 0001589602) files insider reports with the SEC as Director of Theravance Biopharma, Inc. (TBPH) and Director of ARVINAS, INC. (ARVN).

Signal8 holds 5 ownership filings by Smaldone Alsup Laurie, all Form 4s, filed between May 21, 2025 and Sep 24, 2026. Those filings report 6 transactions, from May 19, 2025 to Sep 23, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Smaldone Alsup Laurie's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Smaldone Alsup Laurie

Sep 23, 2026: Disposition to issuer transactions of TBPH shares (2 lines, Form 4, code D).
Jun 24, 2026: Grant or award of ARVN shares (Form 4, code A).
Jun 12, 2026: Grant or award of TBPH shares (Form 4, code A).
Jun 25, 2025: Grant or award of ARVN shares (Form 4, code A).
May 19, 2025: Grant or award of TBPH shares (Form 4, code A).

Other insiders filing for Theravance Biopharma, Inc. (TBPH)

Weiss Asset Management LP, Officer
PAKIANATHAN DEEPIKA, Director
O'Connor Donal, Director
MITCHELL DEAN J, Director
GRAY SUSANNAH, Director
Winningham Rick E, CHIEF EXECUTIVE OFFICER

How to read Form 4 transaction codes